The online version of this article (https://doi.org/10.1007/s12094-018-02015-5) contains supplementary material, which is available to authorized users.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Evidence suggests an excess of long-term mortality due to cardiovascular diseases, second tumours and other causes in patients diagnosed with invasive breast cancer (BC). Our aim was to assess this risk of death in a cohort of patients diagnosed with BC in Girona and Tarragona, northeastern Spain.
Using data from the cancer registries in these areas, a population-based cohort study was carried out including all the women diagnosed with BC during 1985–2004 and followed up until December 31st 2014 (N = 10,195). The standardised mortality ratios (SMRs) were calculated for causes other than BC in the cohort at 10 years (periods 1985–1994/1995–2004) and 20 years (period 1985–1994). The impact of competing causes of death in the long-term survival was evaluated through competing risk analysis.
The SMRs at 10 and 20 years for all-cause mortality, except BC, were 1.21 and 1.22. The main causes of mortality showing statistically significant SMR at 10 years were other tumours (colon, lung, corpus uteri, ovary, and haematological), diabetes mellitus, diseases of the nervous system, cardiovascular diseases (after BC, the second competing cause of death among patients diagnosed > 69 years) and diseases of the kidney. Globally, the 10-year SMR was higher in the first period. After 20 years of follow-up (1985–1994 cohort), there were 48.5 excess deaths per 10,000 patient-years for causes other than BC.
Women who did not die from BC at 10 or 20 years after the BC diagnosis had 20% higher risk of dying from other causes than women without BC. This excess risk must be clinically considered during 20 years after the BC diagnosis.
Supplementary material 1 (DOCX 29 kb)12094_2018_2015_MOESM1_ESM.docx
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365(9472):1687–717. CrossRef
Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70. CrossRef
Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;15(7):9. CrossRef
Clèries R, Ameijide A, Buxó M, Martínez JM, Marcos-Gragera R, Vilardell ML, et al. Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985–2004). Clin Transl Oncol. 2018;20(10):1252–60. CrossRefPubMed
Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ. 1987;82:1–406.
Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr. 1985;68:99–112. PubMed
de Gonzalez AB, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102:220–6. CrossRef
Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015;159(2):439–45.
Molina-Montes E, Pollán M, Payer T, Molina E, Dávila-Arias C, Sánchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130(2):340–5. https://doi.org/10.1016/j.ygyno.2013.04.057. CrossRefPubMed
Haase D, Hanf V, Schulz T. Therapy-related hematologic neoplasias after breast cancer Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results. Med Klin (Munich). 2004;99(9):506–17. CrossRef
Early Breast Cancer Trialists’ Collaborative Group, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35. CrossRef
Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Biol Phys. 2016;94(5):1061–72. CrossRef
- Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona
J. M. Martínez
M. L. Vilardell
J. A. Espinàs
J. M. Borràs
- Springer International Publishing
Clinical and Translational Oncology
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
Neu im Fachgebiet Onkologie
Mail Icon II